Altamira Therapeutics Ltd. (CYTOF)
OTC PINK OTC PINK Primary Summary
Altamira Therapeutics Ltd. (CYTOF) Q4 2024 Earnings Call Transcript
Altamira Therapeutics Ltd. (OTC:CYTOF) Q4 2024 Earnings Call April 30, 2025 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairman and Chief Executive Officer Covadonga Paneda - Chief Operating Officer Operator Good day and welcome to the Altamira Therapeutics' Full Year 2024 Financial Results and Business Update Call.
Altamira Therapeutics Ltd. (CYTOF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Altamira Therapeutics Ltd. ever had a stock split?
Altamira Therapeutics Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Thomas Meyer Ph.D. CEO | OTC PINK Exchange | BMG0360L1349 ISIN |
| US Country | 10 Employees | - Last Dividend | 13 Dec 2023 Last Split | 6 Aug 2014 IPO Date |
Overview
Altamira Therapeutics Ltd. is positioned as a preclinical-stage biopharmaceutical entity, focusing its operations within Switzerland and Australia. The company has carved its niche in developing innovative OligoPhore/SemaPhore platforms, designed notably for the peptide-based nanoparticle-aided delivery of ribonucleic acid (RNA) across extrahepatic tissues. With its origins tracing back to 2003 and initially established as Auris Medical Holding Ltd., it underwent a rebranding to Altamira Therapeutics Ltd. in July 2021, marking a new chapter in its journey. The headquarters of Altamira Therapeutics are strategically located in Hamilton, Bermuda, positioning it advantageously for its global and research-oriented ambitions.
Products and Services
- Bentrio
This innovative product stands out as a drug-free nasal spray, specifically crafted for personal protection against airborne viruses and allergens. Bentrio represents Altamira's foray into the commercial market, aiming to provide a barrier against environmental threats to respiratory health.
- AM-401
AM-401 is in the pipeline as a promising therapeutic candidate for the treatment of KRAS-driven cancer, showcasing Altamira's commitment to tackling challenging oncological diseases through advanced therapeutic interventions.
- AM-411
Specially developed for the treatment of rheumatoid arthritis, AM-411 exemplifies Altamira's dedication to addressing autoimmune diseases with innovative approaches and targeted therapies.
- AM-125
Currently in a phase II clinical trial, AM-125 is engineered for the intranasal treatment of vertigo. This development underscores Altamira's focus on novel delivery systems and treatments for debilitating conditions affecting balance and orientation.
- Keyzilen (AM-101)
Progressing through phase II/III clinical trials, Keyzilen targets the treatment of acute inner ear tinnitus. This product highlights Altamira's pursuit of solutions for conditions that significantly impact the quality of life but are often overlooked in the pharmaceutical landscape.
- Sonsuvi (AM-111)
In phase III of clinical development, Sonsuvi is aimed at the treatment of acute inner ear hearing loss, further demonstrating Altamira Therapeutics' investment in audiological health and its commitment to pioneering treatments for inner ear disorders.
